ALLRHealthcare · BiotechnologyALLR Stock Forecast: Allarity Therapeutics, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Allarity Therapeutics, Inc. hold a median 12-month price target of $10 — +707.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ALLR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Allarity Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (88): Smaller than most of the companies we track.
Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Allarity Therapeutics, Inc. — and when they’d sell — is the membership.
ALLR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ALLR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +707.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | $9.75 → $10 |
| 10 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 9 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 26 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 28 July 2025 | Ascendiant Capital | Initiates | Buy | — |
| 23 Aug 2022 | Ladenburg Thalmann | Downgrade | Neutral | — |
| 27 May 2022 | Ladenburg Thalmann | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ALLR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Allarity Therapeutics, Inc. (ALLR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.1×
- Price / sales
- 57.4×
- Price / book
- 2.8×
- EV / EBITDA
- −1.8×
Cheaper than 72% of US stocks
Cheaper than 5% of US stocks
Cheaper than 35% of US stocks
Cheaper than 71% of US stocks
- Revenue growth (YoY)
- −92.2%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −10752.0%
- Net margin
- 0.0%
Higher than 2% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
- Return on equity
- −87.9%
- Return on assets
- −23.7%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ALLR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALLR appears on the weeks it earns a place.
Frequently asked questions about ALLR stock
What is the ALLR stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Allarity Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ALLR stock a buy right now?
Of the 1 analysts covering Allarity Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Allarity Therapeutics, Inc. 39 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ALLR?
As at 1 Aug 2026, Allarity Therapeutics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).
Will ALLR stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +707.1% from the last close, and Ticker Nerd's factor model ranks Allarity Therapeutics, Inc. 39 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ALLR stock forecast for 2030?
No analyst covering Allarity Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALLR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.
How has ALLR stock performed over the past year?
Allarity Therapeutics, Inc. returned +25.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Allarity Therapeutics, Inc. do?
Allarity Therapeutics is a clinical-stage precision medicine biopharmaceutical company dedicated to developing personalized cancer treatments for patients with difficult-to-treat malignancies. The company's lead program focuses on stenoparib, a novel orally available dual inhibitor of PARP1/2 and tankyrase 1/2, currently in Phase 2 clinical trials for advanced, platinum-resistant, and platinum-ineligible ovarian cancer.
About Allarity Therapeutics, Inc.
Allarity Therapeutics is a clinical-stage precision medicine biopharmaceutical company dedicated to developing personalized cancer treatments for patients with difficult-to-treat malignancies. The company's lead program focuses on stenoparib, a novel orally available dual inhibitor of PARP1/2 and tankyrase 1/2, currently in Phase 2 clinical trials for advanced, platinum-resistant, and platinum-ineligible ovarian cancer. The company received FDA Fast Track designation for stenoparib in ovarian cancer, enabling expedited development and review pathways. A cornerstone of Allarity's strategy is its proprietary Drug Response Predictor (DRP®) companion diagnostic platform, which uses gene expression signatures to identify patients most likely to benefit from specific therapies, enabling a precision medicine approach to oncology. Beyond ovarian cancer, the company is expanding stenoparib's clinical potential into other advanced cancers, including a Phase 2 trial in recurrent small cell lung cancer funded by the U.S. Veterans Administration. Headquartered in the United States with research operations in Denmark, Allarity also generates revenue through licensing and laboratory services agreements that provide external partners access to DRP® diagnostic algorithms and transcriptomic testing services.
CEO Mr. Thomas H. Jensen · 7 employees · United States · https://www.allarity.com